{"brief_title": "AMG 162 in the Treatment of Bone Loss in Subjects Undergoing Androgen-Deprivation Therapy for Non-metastatic Prostate Cancer", "brief_summary": "This study will evaluate AMG 162 in the treatment of bone loss in subjects undergoing Androgen-Deprivation Therapy for Non-metastatic Prostate Cancer.", "condition": ["Prostate Cancer"], "intervention_type": ["Drug", "Drug"], "intervention_name": ["AMG 162", "Placebo"], "description": ["60 mg (1.0mL) administered subcutaneously at Day 1, Months 6, 12, 18, 24, 30", "60 mg (1.0mL) administered subcutaneously at Day 1, Months 6, 12, 18, 24, 30"], "arm_group_label": ["AMG 162", "Placebo"], "criteria": "Other criteria also apply", "gender": "Male", "minimum_age": "18 Years", "maximum_age": "N/A", "healthy_volunteers": "No", "keyword": "Treatment of bone loss in patients undergoing androgen deprivation therapy (ADT) for non-metastatic prostate cancer (PC).", "mesh_term": ["Prostatic Neoplasms", "Denosumab", "Androgens"], "id": "NCT00089674"}